Top Developed Critical Care Therapeutics Markets Analysed by GBI Research in New Cutting-edge Report Published at MarketPublishers.com
31 Jul 2014 • by Natalie Aster
LONDON – The overall value of the critical care market in the leading developed countries is expected to grow from an estimated value of USD 1.8 billion in 2013 to USD 2.5 billion by 2019, posting a forecast-period CAGR of 4.7%. This growth is driven by the approval of novel factor concentrates in the USA recently and the resultant upsurge in their uptake in the future. Factor concentrates are increasingly preferred owing to the lower infection risks posed by them compared to the older alternatives like cryoprecipitate and fresh-frozen plasma (FFP) in critical care units.
The USA accounts for just over 40% of the world critical care market and is anticipated to post a CAGR of 7.5% through to 2020. Both approved in 2013, the first 4-factor prothrombin complex concentrate (PCC) in the US (KCentra) and the first recombinant FXIII concentrate (Tretten) are projected to see robust uptake over the forecast period. Two other factor concentrates approved in the USA in 2009 – human fibrinogen concentrate (RiaSTAP) and recombinant AT concentrate (ATryn) – are also expected to contribute to the sector’s growth. The European critical care therapeutics market is forecast to witness weaker growth, with the UK, France, Germany, Spain and Italy recording CAGRs of 3%, 2.5%, 2.3%, 2.3% and 2%, respectively.
New study “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market” elaborated by GBI Research provides true insights into the critical care therapeutics market in the 8 leading markets, covering market size estimates for 2013 plus detailed forecasts to 2020. It investigates the 5 main plasma-derived products in critical care and the indications being treated using these products, analyses key marketed products’ performance in terms of efficacy and safety of most recent approvals, reviews critical care R&D pipeline. The study canvasses the key unmet needs, investigates the limiters and drivers impacting the sector, examines the competitive scenario, as well as discusses the major deals and strategic consolidations in the field.
Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market
Published: July, 2014
Price: US$ 3,500.00
More new reports by the publisher can be found at GBI Research page.